Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares.
Oncolytics Biotech Trading Down 1.3%
The firm has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The company has a fifty day moving average price of C$14.90 and a 200-day moving average price of C$14.90. The company has a current ratio of 2.88, a quick ratio of 8.86 and a debt-to-equity ratio of 14.58.
Insider Buying and Selling
In other Oncolytics Biotech news, Director Patricia Andrews acquired 35,400 shares of Oncolytics Biotech stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average price of C$1.18 per share, with a total value of C$41,772.00. Following the purchase, the director owned 78,128 shares in the company, valued at approximately C$92,191.04. This trade represents a 82.85% increase in their ownership of the stock. Also, Director Deborah Brown acquired 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average price of C$1.17 per share, with a total value of C$29,250.00. Following the completion of the acquisition, the director directly owned 109,851 shares of the company’s stock, valued at C$128,525.67. This represents a 29.46% increase in their position. Over the last three months, insiders purchased 289,232 shares of company stock valued at $335,760. 3.82% of the stock is owned by company insiders.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
Further Reading
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
